Active — invitation-only current cycle; mandatory preproposal passedAtlas Opportunity Score 89/100
HT942526ORPARA
DoW Orthopaedic, Applied Research Award — HT942526ORPARA
FundingApproximately $3.8 million total program funding; approximately 4 awards; $950,000 total-cost cap per award; maximum 3-year period of performance. No cost sharing required.
DeadlineMandatory preproposal: August 19, 2026 at 5:00 PM Eastern Time. Invitation date: September 25, 2026. Full application: November 18, 2026 at 11:59 PM Eastern Time. Verification ends November 23, 2026 at 5:00 PM Eastern Time.
Last verifiedOctober 7, 2026
Required next actionCurrent-cycle applicants must have submitted the mandatory August 19 preproposal and received an invitation to submit a full application. Verify invitation status, preliminary data, military relevance, preclinical translational readiness, and alignment to an FY26 focus area before preparing the invited application.
Broad Eligibility
Domestic and foreign for-profit and nonprofit organizations and public/private entities are eligible, subject to the program announcement. Independent investigators affiliated with eligible organizations may serve as PI. Cost sharing is not required. Current-cycle progression requires a timely mandatory preproposal and invitation.
Atlas Analysis
Atlas Opportunity Score 89/100. Preferred posture: Partner-Led / Already-Preapplied Orthopaedic Applied Research Team. The mechanism is designed for applied preclinical work supported by preliminary data and strong military relevance. Clinical trials are prohibited. Focus areas include Battlefield Fracture-Related Infection, Composite Tissue Regeneration, Limb Stabilization and Protection, Osseointegration Outcomes, and Return-to-Duty Strategies. Structural eligibility alone does not establish submission readiness.
Federal opportunity identifier: HT942526ORPARA
The FY26 Orthopaedic Applied Research Award supports applied preclinical research addressing military-relevant orthopaedic needs. Preliminary data are required. Clinical trials are not allowed, and clinical research is limited to work that meets the announcement’s applicable exempt or expedited-review conditions.
Funding: Approximately $3.8 million across about four awards, with a $950,000 total-cost cap per award and a maximum three-year period of performance. Cost sharing is not required.
Current-cycle deadlines: The mandatory preproposal deadline was August 19, 2026 at 5:00 PM Eastern Time. Invitations are scheduled for September 25, 2026. Invited full applications are due November 18, 2026 at 11:59 PM Eastern Time.
Because the mandatory first-stage deadline has passed, current-cycle support is restricted to teams that submitted a timely preproposal and, after September 25, receive an invitation. New FY26 applicant outreach should not be initiated for this mechanism.
Source verificationOfficial government source · simpler.grants.govAtlas last verified this record October 7, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
